Dr. Philipp Lange received his PhD in Biochemistry from the Free University Berlin, Germany after earning an MSc in Molecular Biology, Microbiology and Computer Sciences from the University of Hamburg, Germany. During his PhD at the Max Delbruck Centre for Molecular Medicine, Berlin, Germany he studied the molecular causes of hereditary osteopetrosis in children and patented a new drug target for the treatment of osteoporosis in women.
In 2009 he moved to Vancouver, BC for his postdoctoral work with Dr. Christopher Overall. At the Centre for Blood Research, UBC he advanced mass spectrometry based proteomics to study post-translational protein modification in breast cancer. He is also the developer and curator of the biological knowledgebase and data analysis platform TopFIND.
Since 2015 Dr Lange is Assistant Professor in the Department of Pathology and Laboratory Medicine at UBC and Investigator at the BC Children’s Hospital and BC Cancer Research Centre. As Canada Research Chair in ‘Translational Proteomics of Pediatric Malignancies’ he heads an integrated proteomics and bioinformatics driven research program investigating the molecular basis and new treatment avenues in childhood cancer.
Free University of Berlin, PhD, Biochemistry. 2008
University of Hamburg, MSc, Molecular Biology, Microbiology and Computer science. 2004
- Childhood cancer
- Cell signaling
- Protein function
- Post-translational protein modification
- Targeted therapeutics
My research team strives to develop new diagnostic and therapeutic approaches to detect and treat children suffering from cancer earlier, better and with reduced impact on their life.
The fundamental question is how cancer cells are different from healthy, normal cells? If we understand this we will be able to better detect and kill cancer while leaving the rest of the body untouched.
Our research focusses on proteins, the structural and functional building blocks of a cell. To do this we combine genomics and proteomics, a technology that enables us to monitor all of the proteins in our body and detect how they are changed in childhood cancer. We then use computational approaches to further analyze and integrate our findings and to make them accessible to clinicians and fellow scientists around the world.
The overall objective of my team’s research is to monitor and detect aberrant protein presence and function in cancer and exploit this difference to diagnose and treat cancer and improve the wellbeing of cancer survivors.
We are particularly interested in how the post-translational modification of proteins affects cancer progression and secondary disease, which can hit childhood cancer survivors years after successful treatment. After translation proteins can be modified by, for example, proteolytic processing or phosphorylation. This creates a repertoire of “proteoforms”, which are all the variant and modified protein products of a single gene. They often differ in their localization, function and interaction with other proteins.
Current projects in my lab include:
We are hiring.
Opportunities for Students, Postdoctoral Fellows and Research Technicians available! Get in touch.